Ascent Group LLC trimmed its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 8.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,652 shares of the pharmaceutical company's stock after selling 790 shares during the period. Ascent Group LLC's holdings in Vertex Pharmaceuticals were worth $3,852,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently modified their holdings of VRTX. Brighton Jones LLC boosted its holdings in shares of Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock worth $1,783,000 after buying an additional 579 shares in the last quarter. NBC Securities Inc. bought a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $167,000. RFG Advisory LLC boosted its holdings in shares of Vertex Pharmaceuticals by 12.1% during the 1st quarter. RFG Advisory LLC now owns 757 shares of the pharmaceutical company's stock worth $367,000 after buying an additional 82 shares in the last quarter. Chesley Taft & Associates LLC bought a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $236,000. Finally, Foster Group Inc. bought a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $255,000. 90.96% of the stock is currently owned by institutional investors.
Vertex Pharmaceuticals Stock Down 1.4%
VRTX opened at $403.30 on Friday. The company has a market capitalization of $103.40 billion, a price-to-earnings ratio of 28.83 and a beta of 0.43. The firm has a 50-day moving average price of $399.12 and a 200-day moving average price of $442.50. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.88.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. The firm had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company's revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the company earned ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on VRTX shares. Citigroup increased their target price on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a "buy" rating in a report on Thursday. Royal Bank Of Canada cut their target price on Vertex Pharmaceuticals from $430.00 to $405.00 and set a "sector perform" rating on the stock in a report on Tuesday, August 5th. HC Wainwright cut their target price on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating on the stock in a report on Tuesday, August 5th. Leerink Partners upgraded Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating and cut their target price for the stock from $458.00 to $456.00 in a report on Thursday, September 25th. Finally, Scotiabank cut their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a "sector perform" rating on the stock in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $493.81.
Check Out Our Latest Analysis on VRTX
Insiders Place Their Bets
In related news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares of the company's stock, valued at $17,535,600. This represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is owned by insiders.
Vertex Pharmaceuticals Profile
(
Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Further Reading
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
